Aug 08, 2013, 02.18 PM | Source: Moneycontrol.com
Israel-based Taro's first quarter net income declined 7 percent, while revenue fell 4 percent, which the company said was due to a one-time charge taken to meet contractual obligations.
Sun Pharmaceutical Industries shares tumbled 5 percent in morning trade on Thursday after the generics drug maker's subsidiary Taro Pharmaceutical Industries reported a 7 percent year-on-year drop in its first quarter earnings.
Israel-based Taro's first quarter net income dropped to about USD 59 million from about USD 63 million in the year ago quarter. Its net sales in April-June declined 4 percent to USD 153 million.
"The revenue decline is principally due to a net charge taken to meet contractual obligations associated with price adjustments made in the current quarter, the benefit of which should be realized in future periods," Kal Sundaram, CEO, Taro, said in a statement.
Excluding the one-time charge, Taro's sales for the three-month period would have increased over 10 percent year-on-year, Sundaram added.
For Q1, Taro's gross profit as a percentage of sales dropped to 69.7 percent from 71.7 percent. Operating income declined to USD 73.6 million, or 48 percent of net sales, compared with USD 79 million, or 49.6 percent of net sales, it said.
Sun Pharma will announce its first quarter earnings on Friday.
At 9:45hrs, Sun Pharma shares were down 2.1 percent at Rs 511.05 on NSE.
Stay invested in Sun Pharma, says Ashish Kyal
Ashish Kyal of wavesstrategy.com is of the view th
Sun Pharma Advanced Research's Q3 net loss widens to Rs 41 cr
The company had posted a net loss of Rs 18.91 cror
Sun Pharma gains; launches Imatinib Mesylate in US market
The company's subsidiary has received final approv
Sun hopes cut-price generic Gleevec will win third of US market
Gleevec, or imatinib mesylate, costs up to about U
Sun completes sale of 2 Ranbaxy divisions to Strides
Sun Pharma may test Rs 885-900, says Yogesh Mehta
Yogesh Mehta of Motilal Oswal Securities is of the
Lupin, Cipla top picks from pharma space: Parag Thakkar
Parag Thakkar, Head of Sales at HDFC Securities is
Buy Century Textiles, Sun Pharma: Kunal Bothra
Kunal Bothra, Head of Advisory at LKP Securities i